Trial · NCT00553969
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
NCT00553969, Phase 1, Phase 2, Completed, University of Minnesota; results first posted 2014-12-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease. Trials, record NCT00553969. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00553969
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
- NCT number
- NCT00553969
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 101 participants, actual
- Lead sponsor
- University of Minnesota
- Conditions
- Pre-hypertension
- Interventions
- carvedilol phosphate, lisinopril, carvedilol phosphate and lisinopril, placebo and placebo
- First posted
- 2007-11-06
- Last updated
- 2018-04-24
- Results first posted
- 2014-12-17
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Disease Score (DS) Among the Treatment Groups | Baseline and nine months | Rasmussen Disease Score (RDS) Change From Baseline to 9 Months A score of six or higher on these tests means the patient likely has plaque build-up in the arteries, or atherosclerosis, while a score of three to five suggests that such a problem may be developing. A score of two or less signals a patient is fine but should return in the future for another test. The method detects disease at the earliest moment, before the traditionally used calcium score would show any signs of trouble. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Disease Score (DS) Among the Treatment Groups | Baseline and nine months | Calculation for change is the value at the later time point minus the value at the earlier time point. | Overall Rasmussen Disease Score Change | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Disease Score (DS) Among the Treatment Groups | 1 Coreg CR + Lisinopril | -2.48 | Standard Deviation 1.9 | Overall Rasmussen Disease Score Change | |
| Change in Disease Score (DS) Among the Treatment Groups | 2 Coreg CR + Placebo | -2.29 | Standard Deviation 2.3 | Overall Rasmussen Disease Score Change | |
| Change in Disease Score (DS) Among the Treatment Groups | 3 Lisinopril + Placebo | -2.38 | Standard Deviation 2.6 | Overall Rasmussen Disease Score Change | |
| Change in Disease Score (DS) Among the Treatment Groups | 4 Placebo + Placebo | -0.96 | Standard Deviation 1.5 | Overall Rasmussen Disease Score Change |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 1 Coreg CR + Lisinopril | 31 | |
| Overall Study | STARTED | 2 Coreg CR + Placebo | 24 | |
| Overall Study | STARTED | 3 Lisinopril + Placebo | 22 | |
| Overall Study | STARTED | 4 Placebo + Placebo | 24 | |
| Overall Study | COMPLETED | 1 Coreg CR + Lisinopril | 23 | |
| Overall Study | COMPLETED | 2 Coreg CR + Placebo | 24 | |
| Overall Study | COMPLETED | 3 Lisinopril + Placebo | 21 | |
| Overall Study | COMPLETED | 4 Placebo + Placebo | 23 | |
| Overall Study | NOT COMPLETED | 1 Coreg CR + Lisinopril | 8 | |
| Overall Study | NOT COMPLETED | 2 Coreg CR + Placebo | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | stroke | Vascular disorders | 1 Coreg CR + Lisinopril | 0 | 31 | |
| serious | stroke | Vascular disorders | 2 Coreg CR + Placebo | 0 | 24 | |
| serious | stroke | Vascular disorders | 3 Lisinopril + Placebo | 1 | 22 | |
| serious | stroke | Vascular disorders | 4 Placebo + Placebo | 0 | 24 |
Source ClinicalTrials.gov
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 1 Coreg CR + Lisinopril | ||
| Total, all-cause mortality | 2 Coreg CR + Placebo | ||
| Total, all-cause mortality | 3 Lisinopril + Placebo | ||
| Total, all-cause mortality | 4 Placebo + Placebo | ||
| Total, other adverse events | 1 Coreg CR + Lisinopril | 0 | 31 |
| Total, other adverse events | 2 Coreg CR + Placebo | 0 | 24 |
| Total, other adverse events | 3 Lisinopril + Placebo | 0 | 22 |
| Total, other adverse events | 4 Placebo + Placebo | 0 | 24 |
| Total, serious adverse events | 1 Coreg CR + Lisinopril | 0 | 31 |
| Total, serious adverse events | 2 Coreg CR + Placebo | 0 | 24 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00553969
GET https://conductscience.org/api/trials/v1/NCT00553969/registered